University Hospital Plymouth NHS Trust Trials

University Hospital Plymouth NHS Trust	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Shaw, Heather S

EBIN, NCT03235245 / 2017-002887-42: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Active, not recruiting

271

Europe

Nivolumab + Ipilimumab, Encorafenib + Binimetinib

European Organisation for Research and Treatment of Cancer - EORTC

Unresectable Stage III Melanoma, Stage IV Melanoma

10/23

01/27

TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting

850

Europe

Tebentafusp, IMCgp100

University of Oxford, Immunocore Ltd, Natera, Inc.

Melanoma (Skin), Melanoma, Uveal

06/25

06/26

SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting

130

Europe

SCIB1 or iSCIB1+ DNA vaccine

Scancell Ltd, Scancell Ltd

Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV

01/26

IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting

Europe, Canada, US, RoW

Darovasertib, IDE196, LXS196

IDEAYA Biosciences

Uveal Melanoma

01/26

01/29

NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated

Europe

Biological: ATL001

Achilles Therapeutics UK Limited

Melanoma, Advanced Non Small Cell Lung Cancer

10/23

IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Oct 2024 - Dec 2024 : Data for late-line NSCLC

Recruiting

1/2

727

Europe, Canada, US, RoW

Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors

Immunocore Ltd

Select Advanced Solid Tumors

02/26

08/26

NVG111-101, NCT04763083 / 2020-000820-20: First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Recruiting

Europe

NVG-111

NovalGen Ltd.

Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma

12/23

12/25

OMNi, NCT04588662: A Prospective Natural History Study in Uveal Melanoma

Recruiting

N/A

700

Europe, Canada, US, RoW

Columbia University

Uveal Melanoma

07/26

Highley, Martin

SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting

130

Europe

SCIB1 or iSCIB1+ DNA vaccine

Scancell Ltd, Scancell Ltd

Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV

01/26

Mamas, Mamas

NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Recruiting

N/A

3000

Europe

Ultimaster Nagomi™

Terumo Europe N.V.

Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease

09/26

09/27

Young, Kate

iCaD, NCT05947669: Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis

Recruiting

195

Europe

Infliximab, Methylprednisolone, Prednisolone

Odense University Hospital, Aalborg University Hospital, Royal Marsden NHS Foundation Trust

Colitis

09/26

09/28

SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting

130

Europe

SCIB1 or iSCIB1+ DNA vaccine

Scancell Ltd, Scancell Ltd

Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV

01/26

ATRIUM, NCT06605833: A Feasibility Study to Investigate LATe CaRdiac ToxicIty Following ImmUnotherapy Treatment for Melanoma

Not yet recruiting

N/A

Europe

Lead ECG, Transthoracic Echocardiogram, Cardiac MRI, Cardiac Biomarker Screening, Basic Observations

Royal Marsden NHS Foundation Trust, Royal Brompton and Harefield NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust

Melanoma Stage III or IV

11/25

11/26

LATENT, NCT06414343: LATe TreatmENT Related Toxicity in Melanoma

Not yet recruiting

N/A

400

Europe

Observational - no intervention

Royal Marsden NHS Foundation Trust

Melanoma

12/24

PerceIVe, NCT06710093: Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma

Not yet recruiting

N/A

100

Europe

Royal Marsden NHS Foundation Trust

Metastatic Melanoma

01/28

01/29

Aroori, Somaiah

NCT04596865: Recurrence After Whipple's (RAW) Study

Completed

N/A

1484

Europe, RoW

Pancreaticoduodenectomy

University Hospital Plymouth NHS Trust, University of Plymouth

Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma of the Extrahepatic Bile Duct, Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Carcinoma, Surgery, Survivorship, Recurrent Cancer, Cancer Recurrent, Cancer Recurrence, Local Recurrence of Malignant Tumor of Pancreas

03/22

06/23

LIVACOR, NCT05138094: Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection

Recruiting

N/A

Europe, RoW

Minimally invasive simultaneous resection, Minimally invasive combined resection, Minimally invasive synchronous resection, Minimally invasive two-stage resection, Minimally invasive sequential resection

Fondazione Poliambulanza Istituto Ospedaliero, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University Hospital Southampton NHS Foundation Trust, University Hospital Birmingham NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, King's College Hospital NHS Trust, Manchester University NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, University Hospital Plymouth NHS Trust, Mauriziano Umberto I Hospital, University Hospital Padova, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, San Raffaele University Hospital, Italy, Ospedali Riuniti Ancona, Azienda Usl di Bologna, Azienda Ospedaliero-Universitaria di Modena, Federico II University, Parma University Hospital, Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie, Maastricht University Medical Center, University of Navarrra Hospital (Clinica Universitaria), Hospital del Mar, Assistance Publique - Hôpitaux de Paris, Oslo University Hospital, Ziekenhuis Oost-Limburg, General Hospital Groeninge, Moscow Clinical Scientific Center, Centre Hospitalier du Luxembourg

Colorectal Neoplasms Malignant, Neoplasm Metastasis

09/23

09/24

I-FIGS, NCT05616039: Feasibility Study

Active, not recruiting

N/A

Europe

Standard Liver Surgery, Indocyanine Fluorescent Image Guided Surgery (I-FIGS)

University Hospital Plymouth NHS Trust

Liver Cancer, Hepatocellular Carcinoma, Liver Metastasis Colon Cancer

04/24



	Diseases Companies Products Productz Mechanisms of Action Sites